[1]罗丹, 王璞. 静脉血栓栓塞症的抗凝现状及新型抗凝药的研究进展[J]. 现代医药卫生, 2017, 33(21): 3294-3296.
[2]Mandernach MW, Beyth RJ, Rajasekhar A. Apixaban for the prophylaxis and treatment of deep vein thrombosis and pulmonary embolism: an evidence-based review [J]. Ther Clin Risk Manag, 2015, 11: 1273-1282.
[3]何改平, 张彬. 新型口服抗凝药物的研究进展[J]. 医学综述, 2015, 21(8): 1432-1435.
[4]丁征, 潘文斐, 郑英丽. 新型口服抗凝药物及拮抗剂的发展现状与上市研究[J]. 药品评价, 2019, 16(2): 9-12.
[5]Byon W, Nepal S, Schuster AE, et al. Regional gastrointestinal absorption of apixaban in healthy subjects [J]. J Clin Pharmacol, 2018, 58(7): 965-971.
[6]Vakkalagadda B, Frost C, Byon W, et al. Effect of rifampin on the pharmacokinetics of apixaban, an oral direct inhibitor of factor Xa[J]. Am J Cardiovasc Drugs, 2016, 16(2): 119-127.
[7]Frost C, Wang J, Nepal S, et al. Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects [J]. Br J Clin Pharmacol, 2013, 75(2): 476-487.
[8]Frost C, Nepal S, Wang J, et al. Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor Xa inhibitor, in healthy subjects[J]. Br J Clin Pharmacol, 2013, 76(5): 776-786.
[9]Frost C, Shenker A, Jhee S, et al. Evaluation of the single-dose pharmacokinetics and pharmacodynamics of apixaban in healthy Japanese and Caucasian subjects[J]. Clin Pharmacol, 2018,10:153-163.
[10]Raghavan N, Frost CE, Yu Z, et al. Apixaban metabolism and pharmacokinetics after oral administration to humans[J]. Drug Metab Dispos, 2009, 37(1): 74-81.
[11]Song Y, Chang M, Suzuki A, et al. Evaluation of crushed tablet for oral administration and the effect of food on apixaban pharmacokinetics in healthy adults[J]. Clin Ther, 2016, 38(7): 1674-1685.
[12]Song Y, Wang X, Perlstein I, et al. Relative bioavailability of apixaban solution or crushed tablet formulations administered by mouth or nasogastric tube in healthy subjects [J]. Clin Ther, 2015, 37(8): 1703-1712.
[13]Steffel J, Verhamme P, Potpara TS, et al. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation [J]. Eur Heart J, 2018, 39(16): 1330-1393.
[14]Cui Y, Song Y, Wang J, et al. Single- and multiple-dose pharmacokinetics, pharmacodynamics, and safety of apixaban in healthy Chinese subjects [J]. Clin Pharmacol, 2013, 5: 177-184.
[15]Yamahira N, Frost C, Fukase H, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple doses of apixaban in healthy Japanese male subjects [J]. Int J Clin Pharmacol Ther, 2014, 52(7): 564-573.
[16]Byon W, Sweeney K, Frost C, et al. Population pharmacokinetics, pharmacodynamics, and exploratory exposure-response analyses of apixaban in subjects treated for venous thromboembolism [J]. CPT Pharmacometrics Syst Pharmacol, 2017, 6(5): 340-349.
[17]Cirincione B, Kowalski K, Nielsen J, et al. Population pharmacokinetics of apixaban in subjects with nonvalvular atrial fibrillation [J]. CPT Pharmacometrics Syst Pharmacol, 2018, 7(11): 728-738.
[18]Frost CE, Song Y, Shenker A, et al. Effects of age and sex on the single-dose pharmacokinetics and pharmacodynamics of apixaban [J]. Clin Pharmacokinet, 2015, 54(6): 651-662.
[19]Cirincione B, Kowalski K, Nielsen J, et al. Population pharmacokinetics of apixaban in subjects with nonvalvular atrial fibrillation [J]. CPT Pharmacometrics Syst Pharmacol, 2018, 7(11): 728-738.
[20]Kubisz P, Stanciakova L, Dobrotova M, et al. Apixaban-metabolism, pharmacologic properties and drug interactions [J]. Curr Drug Metab, 2017, 18(7): 609-621. |